Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Gene-editing cholesterol treatments could represent a fundamentally new approach to reducing dementia risk. Eli Lilly’s VERVE-102, a base-editing therapy that reduces LDL cholesterol by up to 62% in a single intravenous infusion, offers the first glimpse into whether directly editing genes that control cholesterol can slow cognitive decline—a possibility that could transform dementia prevention for millions of people at genetic risk. Recent research confirms what many neurologists have suspected: cholesterol accumulation in the brain is not simply a byproduct of aging, but an active contributor to the neurological damage underlying dementia, especially in people carrying the APOE4 gene variant.
The connection between cholesterol and dementia is stronger than most people realize. A 2025 meta-analysis of over one million individuals found that even modest cholesterol reductions—just one millimole per liter—lowered dementia risk by up to 80% when using targeted cholesterol-lowering approaches. For people with one copy of the APOE4 gene, the risk of Alzheimer’s disease is four times higher than average; those with two copies face up to a 12-fold increased risk. Gene-editing cholesterol therapies aren’t just theoretical—they’re entering human testing, and early results suggest they could become one of the most durable interventions we’ve seen in dementia prevention.
Table of Contents
- How Does Gene-Editing Lower Cholesterol and Reduce Dementia Risk?
- Understanding the VERVE-102 Gene-Editing Breakthrough and Its Limitations
- The Cholesterol-Brain Connection: How Cholesterol Buildup Damages the Brain in Dementia
- Gene-Editing Versus Statins: How Does This New Approach Compare?
- Safety Concerns and Who This Treatment Is Not Yet For
- Geographic and Population Differences in Cholesterol’s Brain Impact
- What This Research Means for Dementia Prevention in the Next Decade
- Conclusion
How Does Gene-Editing Lower Cholesterol and Reduce Dementia Risk?
Gene-editing therapies like VERVE-102 work by using messenger RNA to instruct liver cells to produce a protein that directly edits the PCSK9 gene, a major regulator of cholesterol levels. When PCSK9 is silenced through this base-editing process, the liver can clear far more LDL cholesterol from the bloodstream. In Eli Lilly’s Phase I trial, a single dose reduced PCSK9 levels by 51% at the lowest dose tested (0.3 mg/kg) and up to 88% at the highest dose (1.0 mg/kg), with corresponding LDL cholesterol reductions ranging from 9% to 62%. This mechanism is different from statins, which slow cholesterol production, or newer monoclonal antibody treatments, which help cells capture LDL—gene editing actually modifies the instruction manual that tells cells how to regulate cholesterol long-term.
The promise for dementia prevention lies in how thoroughly gene-editing can reduce cholesterol. Traditional statins, even among the most effective options like rosuvastatin, work primarily through enzyme inhibition and must be taken indefinitely to maintain cholesterol control. A 2025 meta-analysis examining rosuvastatin across 55 studies and 7 million patients showed it offered the most pronounced protective effect against all-cause dementia among statins studied, but protection required consistent use over at least three years. Gene-editing approaches appear to offer more durable effects with a single infusion, potentially reducing the burden of lifelong medication—though it’s important to note that these therapies are still in early-stage human testing, and longer-term data is needed to confirm durability in preventing dementia specifically.
Understanding the VERVE-102 Gene-Editing Breakthrough and Its Limitations
VERVE-102 represents a significant milestone because it’s the first base-editing gene therapy tested in humans with measurable, dose-dependent results. The therapy uses lipid nanoparticles to deliver genetic instructions to liver cells; these cells then express an adenine base-editor protein that changes a specific letter in the PCSK9 gene, essentially turning it off. Published in The New England Journal of Medicine in May 2026, the Phase I data showed that the therapy maintained its cholesterol-lowering effects over the follow-up period, suggesting the genetic edit may be durable. However, the same trials also documented mild-to-moderate infusion-related reactions in some participants and transient elevations in liver enzymes—side effects that require close monitoring and suggest this approach isn’t risk-free.
The critical limitation is that we don’t yet know whether reducing cholesterol through gene-editing actually prevents dementia in humans. All current dementia-protective evidence comes from studies of statins and other traditional cholesterol-lowering drugs; gene-editing therapies have only demonstrated cholesterol reduction so far. Additionally, VERVE-102 has been tested primarily in people with familial hypercholesterolemia or premature coronary artery disease—relatively younger, healthier populations than the typical dementia patient. The people most at risk for dementia (those with APOE4 genes, older adults, and those with existing cognitive concerns) haven’t yet been studied extensively with these gene-editing approaches. Moving from “lowers cholesterol” to “prevents dementia” requires multi-year clinical trials that won’t be complete for several more years.
The Cholesterol-Brain Connection: How Cholesterol Buildup Damages the Brain in Dementia
The brain uses cholesterol differently than the rest of the body—roughly 25% of the body’s total cholesterol is located in the brain, where it plays a critical role in building and insulating nerve fibers through myelin sheaths. The APOE4 gene variant disrupts this delicate balance by impairing how brain cells manage cholesterol transport and storage. People with APOE4 tend to accumulate cholesterol in their brain tissue, and this buildup interferes with the very myelin insulation that allows neurons to communicate efficiently. Recent research has shown that this cholesterol accumulation also increases amyloid and tau protein pathology—the two main hallmarks of Alzheimer’s disease.
A particularly revealing 2025-2026 study demonstrated this mechanism in action: when researchers treated mice carrying the APOE4 gene with a drug called cyclodextrin that promotes cholesterol transport and reduces buildup in the brain, the animals showed improved myelin formation and significantly better learning and memory performance. This study provides a direct mechanistic link between cholesterol, myelin health, and cognitive function. For people carrying APOE4—roughly 25% of the population has one copy, and 2-3% has two copies—this research explains why their brains are particularly vulnerable to dementia. Reducing their cholesterol levels, whether through traditional statins or emerging gene-editing therapies, addresses a root cause of cognitive decline rather than just treating the end result.
Gene-Editing Versus Statins: How Does This New Approach Compare?
Traditional statins have been the gold standard for cholesterol-lowering and dementia protection for decades. Rosuvastatin, the most effective statin in dementia prevention studies, reduces dementia risk substantially but requires daily pills for years to achieve protection. The advantage of statins is their long safety track record—we have decades of data on millions of patients. The disadvantage is tolerability: some people experience muscle pain, liver enzyme abnormalities, or cognitive side effects with statins, leading them to stop treatment. Statins also work gradually, with cholesterol reductions accumulating over weeks to months.
Gene-editing therapies like VERVE-102 promise a fundamentally different experience: potentially a single infusion, producing rapid and durable cholesterol reduction without daily adherence. For someone at high genetic risk of dementia (such as APOE4 carriers), this could mean addressing the root cause of cholesterol-related neurological damage in one intervention. However, gene editing introduces new uncertainties: these are novel therapies with limited long-term safety data, requiring monitoring in specialized medical centers, and carrying upfront infusion-related reactions in some patients. The practical reality is that statins remain the proven tool for dementia prevention today, while gene-editing represents a promising frontier that could eventually surpass statins—but we won’t know that for years. For most people at dementia risk today, continuing or starting a statin (if medically appropriate) offers immediate, well-established protection.
Safety Concerns and Who This Treatment Is Not Yet For
The Phase I safety data for VERVE-102 was relatively favorable—no dose-limiting toxicities occurred, and most side effects were mild-to-moderate infusion-related reactions (fever, chills, or temporary hypotension that resolved with medical support). However, transient elevations in liver enzymes were noted, requiring liver function monitoring. These early safety signals don’t necessarily predict long-term risks; it typically takes 5-10 years of broader clinical use to identify rare side effects. This is particularly important because gene-editing is permanent—if an adverse effect emerges years later, the genetic change cannot be easily reversed, unlike stopping a medication. Gene-editing therapies like VERVE-102 are not appropriate for everyone at dementia risk.
They’re currently only studied in people with familial hypercholesterolemia or very early coronary artery disease—relatively rare genetic populations. People with APOE4-related dementia risk but normal cholesterol levels wouldn’t be candidates. Pregnant individuals cannot participate in these trials, and the effects on future generations are unknown. Additionally, if someone develops kidney or liver disease, or certain infections, the therapy’s suitability becomes unclear. Most importantly, this approach doesn’t address other major drivers of dementia like hypertension, diabetes, cognitive inactivity, or sleep disruption. Gene-editing cholesterol is one tool in dementia prevention, not a complete solution—and for most people, it remains years away from clinical availability.
Geographic and Population Differences in Cholesterol’s Brain Impact
Research reveals important variations in how cholesterol affects dementia risk across different populations. The 2025 meta-analysis of cholesterol-lowering drugs and dementia found that the greatest protective effects were observed in Asian populations studied, suggesting there may be genetic or environmental interactions that amplify cholesterol’s role in dementia risk in certain groups. Similarly, APOE4 frequency varies globally—it’s more common in European and African populations and less common in East Asian populations, which could partly explain differences in statin-related dementia protection observed across studies.
These geographic variations matter because they suggest gene-editing cholesterol therapies might have different impacts depending on ancestry and genetic background. Someone of European descent carrying two APOE4 copies faces a 12-fold higher dementia risk, and might see substantial cognitive benefit from aggressive cholesterol reduction. Someone with one APOE4 copy in an Asian population might have a different baseline risk and different trajectory of cognitive protection from the same cholesterol reduction. Clinical trials for gene-editing therapies need to include diverse populations to understand who benefits most and whether dosing strategies should differ based on genetic ancestry.
What This Research Means for Dementia Prevention in the Next Decade
The convergence of gene-editing technology, robust cholesterol-dementia evidence, and specific APOE4 understanding suggests dementia prevention is entering a new era. Within the next five years, we expect to see results from Phase II and III trials of VERVE-102 and similar base-editing therapies in people at higher dementia risk, potentially including those with cognitive impairment or APOE4 genotypes. If these trials demonstrate actual dementia risk reduction (not just cholesterol reduction), this would represent a major shift—moving from general cardiovascular health benefits to targeted genetic dementia prevention. The future landscape of dementia prevention might look very different: genetic testing to identify APOE4 carriers in middle age, followed by interventions tailored to their specific risk profile.
Gene-editing therapies could eventually be reserved for those with the highest genetic risk or those who can’t tolerate statins, while statins remain the accessible, proven option for the broader population. Combination approaches might emerge—using gene-editing for cholesterol while addressing blood pressure, blood sugar, and cognitive activity through other means. The key insight from current research is that cholesterol in the brain isn’t just a marker of aging; it’s an active driver of neurological damage that we can now target at the genetic level. How effectively we translate these therapies into dementia prevention depends on completing clinical trials responsibly and making these tools accessible to the populations at highest risk.
Conclusion
Gene-editing cholesterol treatments represent a significant scientific development in dementia prevention, offering the possibility of durable cholesterol reduction through a single genetic intervention rather than lifelong medication. The evidence linking cholesterol, particularly in people carrying APOE4, to dementia risk is now robust and compelling—cholesterol reduction of just one millimole per liter can lower dementia risk by up to 80%. VERVE-102 and similar base-editing therapies have demonstrated that these genetic edits are possible in humans and can produce meaningful cholesterol reductions, but we remain in the early stages of understanding whether they actually prevent dementia.
For most people concerned about dementia risk today, the most practical step is to discuss cholesterol management with a healthcare provider—statins like rosuvastatin have proven dementia-protective effects, especially with consistent use over years. Genetic testing for APOE4 status might be worth considering if you have a family history of dementia or are concerned about your cognitive future. Over the next 5-10 years, watch for results of larger clinical trials of gene-editing therapies in dementia-at-risk populations, but don’t wait passively—known interventions like cholesterol control, blood pressure management, regular cognitive activity, and quality sleep all reduce dementia risk today. The promise of gene-editing is significant, but it complements rather than replaces the fundamental principles of brain health that neurologists have been recommending for years.
You Might Also Like
- Could Editing Cholesterol Genes Affect Dementia Risk?
- Could One Gene Therapy Approach Slow Dementia Damage?
- What a Breakthrough Device Designation Means for Dementia Screening
Related reading
- why Alzheimer’s Treatment May Need More Than One Target
- could Combination Therapy Be the Future of Alzheimer’s Care
- what Families Should Know About the Limits of Amyloid Drugs
- why Some Alzheimer’s Researchers Are Moving Past the Plaque Theory
- could New Drugs Treat Alzheimer’s Before Plaques Build Up
For more on this topic, see CDC — Alzheimer’s and Dementia.
